title: Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
abstract: OBJECTIVE
  To make evidence-based treatment recommendations for patients with Parkinson disease (PD) with dementia, depression, and psychosis based on these questions: 1) What tools are effective to screen for depression, psychosis, and dementia in PD? 2) What are effective treatments for depression and psychosis in PD? 3) What are effective treatments for PD dementia or dementia with Lewy bodies (DLB)?
  
  
  METHODS
  A nine-member multispecialty committee evaluated available evidence from a structured literature review using MEDLINE, and the Cochrane Database of Health and Psychosocial Instruments from 1966 to 2004. Additional articles were identified by panel members.
  
  
  RESULTS
  The Beck Depression Inventory-I, Hamilton Depression Rating Scale, and Montgomery Asberg Depression Rating Scale should be considered to screen for depression in PD (Level B). The Mini-Mental State Examination and the Cambridge Cognitive Examination should be considered to screen for dementia in PD (Level B). Amitriptyline may be considered to treat depression in PD without dementia (Level C). For psychosis in PD, clozapine should be considered (Level B), quetiapine may be considered (Level C), but olanzapine should not be considered (Level B). Donepezil or rivastigmine should be considered for dementia in PD (Level B) and rivastigmine should be considered for DLB (Level B).
  
  
  CONCLUSIONS
  Screening tools are available for depression and dementia in patients with PD, but more specific validated tools are needed. There are no widely used, validated tools for psychosis screening in Parkinson disease (PD). Clozapine successfully treats psychosis in PD. Cholinesterase inhibitors are effective treatments for dementia in PD, but improvement is modest and motor side effects may occur.
authors.affiliation: University of Toronto, Canada.
authors.forename: J M
authors.initials: JM
authors.lastname: Miyasaki
authors.forename: K
authors.initials: K
authors.lastname: Shannon
authors.forename: V
authors.initials: V
authors.lastname: Voon
authors.forename: B
authors.initials: B
authors.lastname: Ravina
authors.forename: G
authors.initials: G
authors.lastname: Kleiner-Fisman
authors.forename: K
authors.initials: K
authors.lastname: Anderson
authors.forename: L M
authors.initials: LM
authors.lastname: Shulman
authors.forename: G
authors.initials: G
authors.lastname: Gronseth
authors.forename: W J
authors.initials: WJ
authors.lastname: Weiner
mesh_terms: D003704:Dementia / Q000209:etiology / Q000628:therapy*; D003863:Depression / Q000209:etiology / Q000628:therapy*; D006801:Humans; D009462:Neurology / Q000592:standards*; D010300:Parkinson Disease / Q000523:psychology* / Q000628:therapy*; D011618:Psychotic Disorders / Q000209:etiology / Q000628:therapy*; D011785:Quality Assurance, Health Care; D014481:United States